Dutch biotech garners €15M in venture round

San Francisco-based Alta Partners took the lead role in a €15 million round of venture financing for Kiadis Pharma, an oncology drug developer. The Amsterdam-based company is developing therapies for bone marrow transplants and the treatment of aggressive cancers. Its four most advanced products are currently in clinical trials, ranging from Phase I to entering Phase III. Kiadis Pharma's lead product is ATIR, which enables the use of mis-matched bone-marrow donors in transplantations for terminally ill blood cancer patients.

- check out the release on the round

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.